Risk of Venous Thromboembolism in Patients Infected with HIV: A Cohort Study

Abstract

Introduction Human immunodeficiency virus (HIV) patients are at risk of developing thrombosis than general population. There are several intersecting mechanisms associated with HIV infection and antiviral therapy that are emerging, which may lead to vasculopathy and hypercoagulability in these patients.

Methods We analyzed the HIV patients who followed up with our Vascular Medicine outpatient clinic with venous thromboembolism (VTE) over the past 3 years and followed them prospectively. The patients included were those who had minimum, regular follow-up of 3 months, with a Doppler scan in the beginning and last follow-up. Patients were analyzed for age, gender, race, site of thrombosis, coagulation factors, lipid panel, type of antiretroviral treatment, past or present history of infections or malignancy, CD4 absolute and helper cell counts at the beginning of thrombosis, response to treatment and outcome. Patients with HIV with arterial thrombosis were excluded.

Results A total of eight patients were analyzed. The mean age was 49.87 years (range, 38–58 years). All were male patients with six patients having lower limb thrombosis, one patient with upper limb thrombosis related to peripheral inserted central catheter (PICC), and one patient had pulmonary embolism with no deep vein thrombosis. Most common venous thrombosis was popliteal vein thrombosis, followed by common femoral, superficial femoral and external iliac thrombosis. Two patients had deficiency of protein S, two had high homocysteine levels, one had deficiency of antithrombin 3, and one had increase in anticardiolipin Immunoglobulin antibody. All patients were taking nucleoside and nonnucleoside inhibitors but only two patients were taking protease inhibitors. There was history of lymphoma in one and nonsmall cell lung carcinoma in one patient. Three patients had past history of tuberculosis and one of these patients also had pneumocystis carinii pneumonia. The mean absolute CD4 counts were 383.25 cells/UL (range, 103–908 cells/UL) and helper CD4 counts were 22.5 cells/UL (range, 12–45 cells/UL). All were anticoagulated with warfarin or enoxaparin. There was complete resolution of deep vein thrombosis in two patients (one with PICC line thrombosis in 3 months and other with popliteal vein thrombosis in 1 year). There was extension of clot in one patient and no resolution in others. Seven patients are still alive and on regular follow-up.

Conclusion Thrombosis in HIV patients is seen more commonly in middle aged, community ambulant male patients. Left lower limb involvement with involvement of popliteal vein is most common. Deficiency of protein S and hyperhomocystenaemia were noted in these patients. Most of these patients did not respond to therapeutic anticoagulation, but the extension of the thrombosis was prevented in majority of cases.

Keywords

anticoagulation - protein C - protein S - homocysteine - antithrombin 3 - duplex - enoxaparin - risk factors

• References

• 1 Bibas M, Biava G, Antinori A. HIV-Associated Venous Thromboembolism. Mediterr J Hematol Infect Dis 2011; 3 (1) e2011030
• 2 Ahonkhai AA, Gebo KA, Streiff MB, Moore RD, Segal JB. Venous thromboembolism in patients with HIV/AIDS: a case-control study. J Acquir Immune Defic Syndr 2008; 48 (3) 310-314
• 3 Klein SK, Slim EJ, de Kruif MD , et al. Is chronic HIV infection associated with venous thrombotic disease? A systematic review. Neth J Med 2005; 63 (4) 129-136
• 4 Saif MW, Greenberg B. HIV and thrombosis: a review. AIDS Patient Care STDS 2001; 15 (1) 15-24
• 5 Lijfering WM, Sprenger HG, Georg RR, van der Meulen PA, van der Meer J. Relationship between progression to AIDS and thrombophilic abnormalities in HIV infection. Clin Chem 2008; 54 (7) 1226-1233
• 6 Jacobson MC, Dezube BJ, Aboulafia DM. Thrombotic complications in patients infected with HIV in the era of highly active antiretroviral therapy: a case series. Clin Infect Dis 2004; 39: 1214-1222
• 7 Shen YM, Frenkel EP. Thrombosis and a hypercoagulable state in HIV-infected patients. Clin Appl Thromb Hemost 2004; 10 (3) 277-280
• 8 Crum-Cianflone NF, Weekes J, Bavaro M. Thromboses among HIV-infected patients during the HAART era. AIDS Patient Care STDS 2008; 22 (10) 771-778
• 9 Orlovic D, Smego RA. Hypercoagulability due to protein S deficiency in HIV-seropositive patients. Int J Collab Res Inter Med Public Health 2009; 1 (6–7) 187-193
• 10 Stahl CP, Wideman CS, Spira TJ, Haff EC, Hixon GJ, Evatt BL. Protein S deficiency in men with long-term human immunodeficiency virus infection. Blood 1993; 81 (7) 1801-1807
• 11 Erbe M, Rickerts V, Bauersachs RM, Lindhoff-Last E. Acquired protein C and protein S deficiency in HIV-infected patients. Clin Appl Thromb Hemost 2003; 9 (4) 325-331
• 12 Parruti G, Manzoli L, Di Iorio G , et al. Plasma homocysteine levels in an Italian cohort of HIV infected patients. International AIDS society 2012; The 3rd IAS Conference on HIV Pathogenesis and Treatment; Abstract no. 2177530
• 13 Brey RL, Arroyo R, Boswell RN. Cerebrospinal fluid anti-cardiolipin antibodies in patients with HIV-1 infection. J Acquir Immune Defic Syndr 1991; 4 (4) 435-441
• 14 Maclean C, Flegg PJ, Kilpatrick DC. Anti-cardiolipin antibodies and HIV infection. Clin Exp Immunol 1990; 81 (2) 263-266
• 15 Coll Daroca J, Gutiérrez-Cebollada J, Yazbeck H, Bergés A, Rubiés-Prat J. Anticardiolipin antibodies and acquired immunodeficiency syndrome: prognostic marker or association with HIV infection?. Infection 1992; 20 (3) 140-142
• 16 Love PE, Santoro SA. Antiphospholipid antibodies; anticardiolipin and the lupus anticoagulant in systemic lupus erthematosus (SLE) and in non-SLE disorders. Ann Intern Med 1990; 2: 682-698
• 17 Viscarello RR, Williams CJ, DeGennaro NJ, Hobbins JC. Prevalence and prognostic significance of anticardiolipin antibodies in pregnancies complicated by human immunodeficiency virus-1 infection. Am J Obstet Gynecol 1992; 167 (4, Pt 1) 1080-1085
• 18 Barbaro G. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection. Curr HIV Res 2006; 4 (1) 79-85
• 19 Koppel K, Bratt G, Schulman S, Bylund H, Sandström E. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 29 (5) 441-449
• 20 Majluf-Cruz A, Silva-Estrada M, Sánchez-Barboza R , et al. Venous thrombosis among patients with AIDS. Clin Appl Thromb Hemost 2004; 10 (1) 19-25
• 21 Goldstein KM, Gluckman S, Mounzer K. Challenge of coadministering antiretroviral therapy and oral anticoagulants in HIV-positive patients. AIDS Read 2008; 18 (9) 480-482 , 486–489